AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 12 min read$BEAM

Evans John M. sold $1.7M of BEAM

Evans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $34.90 ($34.26–$35.91, $1.75M total) across 4 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Evans John M.
Published Jul 1, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BEAM
Neutral
high confidence
Mentioned
$BEAM
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMNeutralLow
01

Why it matters

The disclosure updates insider activity records and can marginally influence sentiment, but it does not introduce new company fundamentals or forward-looking commitments.

02

Market read

Track as a sentiment datapoint for BEAM, but expect limited trading impact absent additional catalysts.

03

What to watch

The filing does not disclose reasons for the sale or any concurrent changes in guidance, trials, or financing—so the signal-to-noise for price action is low.

Relevance 5/10Novelty 3/10Timing: Filed July 1, covering sales executed June 29–30

Background

The article is an SEC Form 4 insider transaction: CEO John M. Evans sold shares of Beam Therapeutics in open-market trades.

Company-level read

Ticker impact

$BEAMNeutralHigh confidence
Context

Beam Therapeutics CEO John M. Evans sold about 50,000 shares in open-market trades totaling ~$1.75M under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and it provides no new operational/financial guidance or material corporate event.

Market effects

Sector

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying company-specific catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may be less informative than discretionary selling; traders may discount it.

Key entities

  • issuer
    Beam Therapeutics Inc.

    Subject of the Form 4 insider transaction; CEO John M. Evans sold shares totaling ~$1.75M under a 10b5-1 plan.

  • insider
    John M. Evans

    CEO of Beam Therapeutics; executed open-market sales across four trades (June 29–30).

Read at source← All news

Related articles

AUG 5
$BEAMMed

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Beam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.

finance.yahoo.com6 min
AUG 4
$BEAMMed

Beam Therapeutics Inc. (BEAM): Results of Operations and Financial Condition

Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Se

SEC EDGAR 8-K4 min
JUL 8
$BEAMMedAI 8/10

Why is Beam Therapeutics stock sliding today? By Investing.com

Beam Therapeutics shares fell about 5% after an arbitration tribunal ruled for Prime Medicine in a dispute over rights to PM647, an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency. The tribunal said PM647 is within Prime’s licensed “Field” under a 2019 agreement. The move followed a recent 52-week high and an H.C. Wainwright Buy rating with an $80 target, while broader equities declined on renewed geopolitical risk.

investing.com3 min